BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for aficamten.

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

The latest trends in cell therapies indicate a growing confidence in their effectiveness, an expansion of applications beyond oncology and significant market growth potential. However, the industry ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.

At the ESCMID Global conference in Austria, the development of climate-informed infectious disease risk management systems was discussed.

Concerns over a potential US recession this year are growing as investors assess the impact of Trump's tariff policies.

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.

The FDA will require an additional Phase III trial for apraglutide, the company's candidate for short bowel syndrome.

Reveal Genomics and Ona Therapeutics have entered a strategic partnership to expedite the clinical development of ONA-255.

AI tools are faster at drafting clinical trial documents, but human writers remain indispensable for logical reasoning.

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.